synthesis and biological evaluation
Recently Published Documents





2022 ◽  
Vol 230 ◽  
pp. 114107
Xin Deng ◽  
Qianqian Qiu ◽  
Baowei Yang ◽  
Xuekun Wang ◽  
Wenlong Huang ◽  

Biomolecules ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 131
Thibaut Barbier ◽  
Alexia Barbry ◽  
Jérémy Magand ◽  
Cédric Badiou ◽  
Floriane Davy ◽  

The benzo[b]thiophene nucleus and the acylhydrazone functional group were combined to prepare three new series of compounds for screening against Staphylococcus aureus. The reaction of substituted benzo[b]thiophene-2-carboxylic hydrazide and various aromatic or heteroaromatic aldehydes led to a collection of 26 final products with extensive structural diversification on the aromatic ring and on position 6 of the benzo[b]thiophene nucleus. The screening lead to the identification of eight hits, including (E)-6-chloro-N’-(pyridin-2-ylmethylene)benzo[b]thiophene-2-carbohydrazide (II.b), a non-cytotoxic derivative showing a minimal inhibitory concentration of 4 µg/mL on three S. aureus strains, among which were a reference classical strain and two clinically isolated strains resistant to methicillin and daptomycin, respectively.

2022 ◽  
Vol 7 (2) ◽  
Bin Wang ◽  
Zongyu Cai ◽  
Siliang Chen ◽  
Ya Chen ◽  
Shixuan Jiao ◽  

Sri Ranga. T ◽  
Neelesh Chaubey

The present investigation is aimed to synthesize fluorobenzothiazole comprising sulphonamido pyrazole analogs starting from fluoro-chloroaniline  to get 2-amino-6-fluoro-7-chloro (1,3) benzothiazole (I), this was treated with anilino-s-methyl ethylene cyanoacetamide  in the presence of ethanol to get desired molecules. The synthesized targeted molecules are characterized, docked and screened  for their invitro antidiabetic properties. Keywords: Fluorobenzothiazole, Docking, antidiabetic

Molecules ◽  
2022 ◽  
Vol 27 (2) ◽  
pp. 461
Arthit Makarasen ◽  
Suwicha Patnin ◽  
Pongsit Vijitphan ◽  
Nanthawan Reukngam ◽  
Panita Khlaychan ◽  

New target molecules, namely, 2-phenylamino-4-phenoxyquinoline derivatives, were designed using a molecular hybridization approach, which was accomplished by fusing the pharmacophore structures of three currently available drugs: nevirapine, efavirenz, and rilpivirine. The discovery of disubstituted quinoline indicated that the pyridinylamino substituent at the 2-position of quinoline plays an important role in its inhibitory activity against HIV-1 RT. The highly potent HIV-1 RT inhibitors, namely, 4-(2′,6′-dimethyl-4′-formylphenoxy)-2-(5″-cyanopyridin-2″ylamino)quinoline (6b) and 4-(2′,6′-dimethyl-4′-cyanophenoxy)-2-(5″-cyanopyridin-2″ylamino)quinoline (6d) exhibited half-maximal inhibitory concentrations (IC50) of 1.93 and 1.22 µM, respectively, which are similar to that of nevirapine (IC50 = 1.05 µM). The molecular docking results for these two compounds showed that both compounds interacted with Lys101, His235, and Pro236 residues through hydrogen bonding and interacted with Tyr188, Trp229, and Tyr318 residues through π–π stacking in HIV-1 RT. Interestingly, 6b was highly cytotoxic against MOLT-3 (acute lymphoblastic leukemia), HeLA (cervical carcinoma), and HL-60 (promyeloblast) cells with IC50 values of 12.7 ± 1.1, 25.7 ± 0.8, and 20.5 ± 2.1 µM, respectively. However, 6b and 6d had very low and no cytotoxicity, respectively, to-ward normal embryonic lung (MRC-5) cells. Therefore, the synthesis and biological evaluation of 2-phenylamino-4-phenoxyquinoline derivatives can serve as an excellent basis for the development of highly effective anti-HIV-1 and anticancer agents in the near future.

Sign in / Sign up

Export Citation Format

Share Document